Clinical TrialMay 20, 2026, 08:02 AM
Telomir Pharma Reports Preclinical Data for Telomir-Zn in Wilson's Disease
AI Summary
Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for Telomir-Zn in the journal Advances in Redox Research. The study demonstrated dose-dependent survival improvement and multiple endpoint benefits in a zebrafish model of Wilson's disease, including reduced oxidative stress, hepatic copper accumulation, and improved liver biomarkers. These findings support the biological activity of Telomir-Zn and its broader mechanistic profile, as the company advances its lead program in Triple-Negative Breast Cancer.
Key Highlights
- Telomir-Zn demonstrated dose-dependent survival improvement in a preclinical Wilson's disease model.
- The study showed reductions in copper-associated oxidative stress and hepatic copper burden.
- Improvements were observed in liver injury biomarkers (ALT, AST, bilirubin) and locomotor function.
- Telomir-Zn attenuated intracellular calcium dysregulation and reduced hepatorenal histopathological degeneration.
- The findings support Telomir-Zn's mechanistic relevance for oxidative stress and dysregulated metal homeostasis.
- This is Telomir-Zn's first peer-reviewed publication in Wilson's disease.
- The company is advancing its lead program in Triple-Negative Breast Cancer toward Phase 1/2 clinical initiation.
Price Impact
More from TELO